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The low bioavailability and nonspecific distribution of dapsone and clofazimine,
commonly applied in combination for the treatment of leprosy, can produce toxic
effects. Nanotechnological approaches enhance the delivery of these drugs. There-
fore, a high-performance liquid chromatography method was developed for the simul-
taneous determination of dapsone and clofazimine loaded in nanoformulations for
quality control purposes. Chromatographic separation was achieved on a reversed-
phase Kinetex core-shell C18 column, followed by spectrophotometric detection at
280 nm. Considering the different physicochemical properties of dapsone and clo-
fazimine, elution was performed in gradient mode using an aqueous acetate buffer
(50 mmol/L, pH 4.8) and an increasing acetonitrile content from 27 to 63% v/v at a
flow rate of 1.0 mL/min with retention times of 6.2 and 14.0 min, respectively. The
method was validated according to the European Medicines Agency guideline and it
was found to be specific, accurate (99.6–114.0%), and precise for intra- (RSD≤ 1.8%)
and interday assays (RSD ≤ 12.5%). Both drugs showed stability after 24 h at room
temperature and over three freeze–thaw cycles with recoveries ≥86.2%. Low temper-
ature (4◦C) in the autosampler caused the precipitation of clofazimine and must be
avoided. The validated method was successfully applied in the quantification of both
drugs in nanoformulations.
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1 INTRODUCTION
Leprosy is a chronic infectious disease caused by Mycobac-
terium leprae, an intracellular bacillus transmitted from an
infected person to others through body fluids, representing
a public health threat in several countries, namely, in India,
Brazil, and Indonesia [1]. The current treatment of this dis-
ease is based on a multidrug therapy that includes combina-
tions of dapsone (DAP), clofazimine (CLZ), and rifampicin
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to treat multibacillary leprosy, and combination of DAP
with rifampicin for treatment of paucibacillary leprosy [2,3].
Although the multidrug therapy shows a good efficacy in the
treatment of leprosy, many patients develop potentially harm-
ful side effects that may occur during or after treatment with
these drugs [4].
DAP (4-[(4-aminobenzene)sulfonyl]aniline) is an aniline
derivative included in the group of synthetic sulfones. Sol-
ubility of DAP varies over a wide range depending on the sol-
vent used, but in general, this compound shows low solubility,
found to result in a low therapeutic index and high micro-
bial resistance. The mechanism of action is characterized
by dual function, with antimicrobial and anti-inflammatory
properties [5]. CLZ (N,5-bis(4-chlorophenyl)-3-(propano-
2-ylimino)-3,5-dihydrophenazin-2-amine), a lipophilic rhi-
mophenazine dye, also possesses antimicrobial and anti-
inflammatory activities [6].
The use of nanotechnological tools to enhance the deliv-
ery of these drugs has been proposed to improve their effi-
cacy, bioavailability, and to reduce unwanted toxic effects [7–
13]. In this context, several methods have been reported for
the determination of DAP and CLZ in different samples,
including pharmaceutical formulations [14], human and rat
plasma [15,16], human blood [17], and tissues [18]. Besides
direct UV methods [19,20], HPLC methods in combination
with UV or MS are most frequently used for the determina-
tion of these compounds.MS detection is a sensitive technique
but it requires special equipments and highly skilled operators.
Moreover, the expected drug levels in nanoformulations can
be reached by UV detection, despite its lower sensitivity [21].
The determination of drug loading in nanodelivery systems
is still an active topic of research, comprising approaches that
provide the total amount of drug [22–25] or that can distin-
guish between the free and the entrapped drug [26–28]. The
last approach is highly time-consuming, as additional sepa-
ration process (SPE, ultrafiltration) must be applied, making
it more suitable for pharmacokinetic/pharmacodynamic stud-
ies where the effective concentration of free drug must be
known. For quality control purposes or assessment of entrap-
ment efficiency, the determination of total loaded drug is suf-
ficient, provided that the preparation media containing free
drug is removed and that disruption of nanoparticles is estab-
lished. This last approach is also advantageous when com-
pared to the evaluation of drug loading based on measurement
of the drug remaining on the supernatant during nanoparticles
preparation.
To the best of our knowledge, there is no chromatographic
method that allows the simultaneous determination of DAP
and CLZ, either free or loaded in nanoparticles. Therefore,
the aim of this work was the development and validation of an
HPLC–UV method for the quantification of both compounds
in a single run for estimation of entrapment efficiency during
the development of nanoformulations of DAP and CLZ.
2 MATERIALS AND METHODS
2.1 Chemicals and solutions
DAP (4-[(4-aminobenzene)sulfonyl]aniline), CLZ (N,5-bis
(4-chlorophenyl)-3-(propano-2-ylimino)-3,5-dihydrophen-
azin-2-amine), polyvinyl alcohol (PVA), Tween® 80,
and sodium acetate were purchased from Sigma-Aldrich (St
Louis, MO, USA). ACN (LiChrosolv HPLC grade), methanol
(LiChrosolv HPLC grade), and acetic acid were obtained
from VWR Chemicals (Radnor, PA, USA). Water from
arium water purification system (resistivity > 18 MΩ cm,
Sartorius, Goettingen, Germany) was used for the preparation
of solutions. Poly(lactic-co-glycolic acid) (PLGA) (50:50
Purasorb® PDLG 5002A) was a kind gift from Purac Bioma-
terials (Gorinchem, The Netherlands). Polyvinylpyrrolidone
K30 was obtained from Fluka (Buchs, Switzerland).
Acetic acid/acetate buffer (50mM, pH 4.8) was prepared by
dissolving 10.20 g of sodium acetate in ca. 100 mL of water,
followed by addition of 2.86 mL of acetic acid, and water up to
250 mL. The buffer solution was then filtered using 0.22 μm
Millipore GVWP filter and degassed in an ultrasonic bath for
30 min prior to use. Other components of the mobile phase
were degassed likewise.
Stock standard solutions of DAP and CLZ were prepared in
ACN at 1.0 and 0.5 g/L, respectively. All stock standard solu-
tions were stored at 4◦C protected from light and used within
seven days. The intermediate solution containing 100 mg/L of
each analyte was prepared daily in ACN/water/acetate buffer
(pH 4.8; 50 mM) (40:50:10 v/v). Working standards were
prepared from the intermediate solution, ranging from 0.5 to
5.0 mg/L, using the same solvent.
2.2 Chromatographic analysis
Chromatographic analysis was performed on JascoHPLC sys-
tem (Easton, PA, USA) equipped with a PU-2089 pump, an
AS-2057 autosampler, a LC-Net II/ADC controller, and a
Jasco MD-2015 photo diode array detector. Standards and
samples were injected (20 μL) into a reversed-phase Kinetex
core–shell C18 column (250 × 4.6 mm; 5 μm particle size;
100 A˚).
The system was run in gradient mode using a mobile phase
consisting of three components: (A) ACN/water (30:70),
(B) ACN/water (90:10), and (C) acetic acid/acetate buffer
(pH 4.8, 50 mM). Hence, gradient elution mode was per-
formed by increasing ACN content from 27 to 63% v/v, and
maintaining a constant concentration of acetic acid/acetate
buffer (pH 4.8, 50 mM) with a total flow rate of 1.0 mL/min.
Initial experiments using ACN < 27% v/v required an extra
solvent line (D) containing deionized water. Determinations
were performed at room temperature (RT) (20 ± 2◦C) and the
detection wavelength was 280 nm.
2.3 Method validation
The chromatographic method was validated for specificity,
linearity, working range, accuracy, intra- and interday preci-
sion, LOD, LOQ, and stability in accordance with European
Medicines Agency and International Conference on Harmon-
isation of Technical Requirements for Registration of Phar-
maceuticals for Human Use guidelines [29,30].
Specificity was determined by analyzing six blanks of
nanoformulations. To evaluate linearity, calibration curves
were prepared and analyzed in triplicate, comprising three
independent experiments. Data were fitted to least squares lin-
ear regression concerning peak area versus concentration for
six standards prepared in mobile phase (0.5, 1, 2, 3, 4, and
5mg/L) and by analysis of the respective response factors (i.e.,
peak area divided by concentration of each standard sample).
Back-calculated concentrations were also obtained.
The accuracy and precision of the assay were assessed by
analyzing quality control (QC) samples at three concentra-
tions levels (0.5, 2, and 5 mg/L). Accuracy (%) was deter-
mined from the percentage ratio of the measured nominal
concentration ((mean of measured concentration) / (nominal
concentration) × 100%). Precision was evaluated by the coef-
ficient of variation ((standard deviation/mean of measured
concentration) × 100%).
Intraday (within-run) values were obtained by replicate
analyses (n = 6) followed by interpolation in calibration
curves prepared on the same day. Interday (between-run) val-
ues were obtained from three independent experiments.
LOD and LOQ values for DAP and CLZ in each matrix
(n= 10) were determined by the S/N ratio, defined as the con-
centrations that originated S/N = 3:1 and 10:1, respectively.
The short-term stability was assessed by maintaining the
QC samples at RT for 24 h. Freeze–thaw stability of the sam-
ples was obtained over three freeze-thaw cycles, by thawing
at RT for 2 h and refreezing for 24 h. Autosampler stability
of DAP/CLZ was tested by analysis of QC samples, which
were stored in the autosampler tray of the HPLC instrument
for 24 h at 4◦C. The concentration of DAP and CLZ after
each storage period was compared to the nominal concentra-
tion determined for the fresh samples, processed immediately
after preparation.
2.4 Preparation, characterization of
nanoformulations, and application to biological
system
DAP polymeric dispersions were prepared by the freeze-
drying method described previously [8]. At first, 200 mg of
DAP and 1000 mg of Polyvinylpyrrolidone K30 were dis-
solved in ACN and water, respectively. After 48 h under mag-
netic stirring (RT 15 Power IKAMAG, Staufen, Germany),
the solutions were then frozen at –84◦C for 24 h. The samples
were freeze-dried (Lyoquest ECO, Telstar) using a condenser
temperature of –65◦C and pressure of 0.5 mbar, during 48 h,
in order to obtain a dry cake. The samples were stored in des-
iccator for a complete drying.
CLZ was loaded in polymeric nanoparticles of PLGA
using the single emulsion-solvent evaporation technique [7].
Briefly, 40 mg of PLGA and 4 mg of CLZ were dissolved in
acetone, and then poured slowly to 10 mL of an aqueous solu-
tion of PVA 1% w/v, under probe sonication with 70% ampli-
tude. After 2 min, the volume was set up to 20 mL with the
PVA solution (0.1% w/v). The final emulsion was maintained
under magnetic stirring (RT 15 Power IKAMAG) at 350 rpm
and RT until solvent evaporation. The obtained nanoparticles
were washed three times with double deionized water, by cen-
trifugation at 11 200 × g for 30 min, using an Allegra X-15R
centrifuge (Beckman Coulter, Brea, CA, USA).
The nanoformulations were characterized in terms of par-
ticle size and polydispersity index (PDI) through dynamic
light scattering (DLS) using a ZetaPALS, Zeta Potential Ana-
lyzer (Brookhaven Instrument Corps, Holtsville, NY, USA),
at 25◦C with a light incidence angle of 90◦. The nanoformula-
tions were diluted with double deionized water until reaching
a suitable concentration for the DLS measurement (count rate
around 500). The nanoformulations were analyzed by HPLC
within one week of preparation.
For permeability studies in biological systems, intestinal
Caco-2 cells were selected, cultivated until forming a mono-
layer and incubated with a combination of nanoparticles con-
taining DAP and CLZ (80 and 40 μg, respectively) in the api-
cal side of the cell monolayer, at 37◦C and 5% v/v CO2 [31].
The amount of DAP and CLZ that permeated the monolay-
ers was calculated from the concentrations measured in the
basolateral compartment and expressed as a percentage of the
initial added amount in the apical compartment.
3 RESULTS AND DISCUSSION
3.1 Selection of chromatographic conditions
DAP (Figure 1) is classified as a class II drug according to the
Biopharmaceutics Classification System, and has high perme-
ability and low solubility in water (log D = 1.27, pH > 4.4,
Supporting Information Figure S1), presenting neutral charge
for pH values > 4 (Supporting Information Figure S2). CLZ
(Figure 1) is a highly hydrophobic molecule (log D = 4.8 at
pH 4.0, and log D = 7.3 at pH > 7.6, Supporting Information
Figure S3). For pH values between 2.3 and 6.6, the positively
charged species is predominant, with ionization occurring by
protonation of the imine group and/or of the nitrogen atom
of the dihydrophenazine heterocycle (Supporting Information
Figure S4). For pH values above 6.6, the neutral form pre-
vails, accounting for the significant decrease CLZ solubility
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F IGURE 1 Chemical structures of DAP and CLZ
in aqueous phases. Hence, isocratic elution was not possible
because the two analytes have substantially different physico-
chemical features at pH values compatible with operation in
derivatized C18-silica columns. Therefore, the gradient elu-
tion was tested, using ACN as organic modifier and keeping a
constant pH (4.8) by addition of acetic acid/acetate buffer at a
constant fixed amount (10% v/v).
Initially, the organic modifier amount in the beginning of
the chromatographic run was tested from 20 to 40% v/v. ACN
content was increased up to 80% v/v by the end of the gradient,
implemented during 30 min, starting from 3 min after sample
injection. DAP was eluted within the gradient for initial ACN
content of 21 and 27% v/v at 8.5 and 5.7 min, respectively.
Elution at 3.7 min was observed for an initial ACN content
at 39% v/v, close to the baseline disturbance associated to the
column void volume (corresponding to ca. 2.5 min). There-
fore, initial content of ACN was fixed at 27% v/v to minimize
the retention of DAP but still separating it from nonretained
compounds present in the sample that will leave the column
at void volume.
Concerning CLZ, elution took place within the gradient at
26.1, 24.4, and 19.4 min for an initial ACN content of 21, 27,
and 39% v/v, respectively. Considering that the gradient was
implemented during 30 min and it started from 3 min after
sample injection, the estimated percentage of ACN content
required for CLZ elution (based on retention time) was 62%
v/v. Therefore, further experiments were performed to estab-
lish the ACN content at the end of the gradient, using ACN
at 54, 60, 63, 66, and 72% v/v. Elution within the gradient
was observed for ACN content above 63% v/v, with retention
time < 33 min. For 54 and 60% v/v, retention time of 38.2
and 34.3 min was observed, with a 10% decrease in the area
attained for ACN at 54% v/v, probably due to incomplete elu-
tion of CLZ from the column. Hence, for further experiments,
ACN content at 60% v/v was chosen as target organic modifier
composition at the end of gradient.
Subsequently, the time required for gradient implementa-
tion was evaluated between 3 and 30 min, starting from 3 min
after sample injection. The retention time for CLZ decreased
from 34.6 to 15 min when the gradient was narrowed from 30
to 3 min. However, DAP peak was affected by baseline dis-
turbance upon the sudden change in mobile phase composi-
tion. To circumvent this problem, the gradient beginning was
delayed to 7 min after sample injection. The retention time for
CLZ was then decreased from 38.3 to 17.6 min when the gra-
dient was narrowed from 30 to 1 min, without jeopardizing
the DAP analysis. A further decrease of gradient beginning
time to 5 min reduced even more the retention time of CLZ to
15.5 min. Further experiments were performed with a higher
ACN content at the end of the gradient (63% v/v), providing a
retention time of CLZ of 14 min. Using these conditions, DAP
retention time was 6.2 min. Column equilibration to initial run
condition was achieved by reducing ACN content to 27% v/v
F IGURE 2 Chromatograms of DAP and CLZ (2 mg/L). The
organic modifier (ACN) content during gradient elution is indicated in
the bar above the graph. Dotted lines indicate gradient correspondence
to the run time minus the time corresponding to the void volume
in 2 min and by keeping this composition during 5 min, pro-
viding a total run time of 23 min (Figure 2).
Different injection volumes (10, 20, and 50 μL) were also
tested using standards containing 1 and 5 mg/L. Calibration
curves were established as absorbance versus injected mass.
For both compounds, mass back-calculation provided values
corresponding to 93.7–119% of injected mass, except for the
injection volume of 10 μL using 1 mg/L of CLZ, for which an
overestimation was observed. Therefore, the injection volume
of 20 μL was chosen for further work. Nevertheless, the cali-
bration range can be moved for higher concentrations (injec-
tion volume of 10 μL, standards above 1 mg/L) or to lower
concentrations (injection volume of 50 μL), with acceptable
mass recoveries.
3.2 Method validation
The validation of the analytical HPLC method was carried
out by evaluating its selectivity, linearity, intra- and interday
precision and accuracy, and stability.
For selectivity, analyses of blank samples of unloaded
nanoformulations were performed as shown in Supporting
Information Figure S5, where a chromatogram for DAP+CLZ
standard is also presented. No interference from compounds
present in the nanoformulations was observed as no peaks
were seen at the retention times of target compounds (Sup-
porting Information Figure S5).
The calibration curves for DAP and CLZ were linear and
reproducible over the concentrations range, with correla-
tion coefficients > 0.9979. Typical calibration curves were
y = (55.0 ± 0.8) × 103 x – 1561 ± 2344 for DAP, and y =
(70.6 ± 0.9) × 103 x – 2039 ± 3004 for CLZ. The back-
calculated concentrations presented deviations <15% from
the nominal value, meeting the requirements of European
Medicines Agency guideline. The calculated values of LOD
and LOQ were 7 and 17 μg/L for DAP, 31 and 65 μg/L for
CLZ.
TABLE 1 Accuracy and precision for the analysis of DAP and CLZ
Intraday Interday
Measured concentration (mg/L) Measured concentration (mg/L)
Compound
Nominal concentration
(mg/L) Mean (mg/L) Accuracy (%) CV (%) Mean (mg/L) Accuracy (%) CV (%)
DAP 0.50 0.55 110 1.8 0.56 112 12.5
2 2.01 100.5 0.5 2.07 103.5 2.4
5 5.22 104.4 1 5.24 104.8 1.3
CLZ 0.50 0.57 114 1.8 0.53 106 9.4
2 2.04 102 1 1.98 99 4.5
5 4.98 99.6 0.8 4.79 95.8 10
The intraday precision and accuracy were calculated by
analyzing the QC samples at low, middle, and high values
(0.5, 2.0, and 5.0 mg/L, Table 1). The intraday precision for
DAP and CLZ was ≤ 1.8%, and accuracy ranged between
100.5 and 110.0% for DAP, and between 99.6 and 114.0% for
CLZ. The interday precision for DAP and CLZ was ≤ 12.5%,
and accuracy ranged between 103.5 and 112.0% for DAP, and
between 95.8 and 106.0% for CLZ. Both intra- and interday
precision, as well as accuracy presented acceptable values for
the two compounds, because precision for each concentration
levels, represented as CV, did not exceed 15%, and the accu-
racy range was between 95.8 and 114.0%.
The stability of DAP and CLZ at laboratory temperature
and in the autosampler was assessed by analyzing fresh sam-
ples and reanalyzing them after being kept during 24 h at RT
(20 ± 2◦C). DAP and CLZ showed stability after this period
as depicted in Table 2, with recoveries ranging from 86.2
to 114.0%. However, when stored in the autosampler during
24 h at 4◦C, precipitation was visible. CLZ deposition
was confirmed when standards containing only this com-
pound were tested. Therefore, samples must be placed in the
autosampler at RT. The freeze–thaw stability of DAP andCLZ
over three freeze–thaw cycles was also assessed, providing
recovery values of 95.4–108.0% (Table 2), showing the stabil-
ity during sample storage and handling. Moreover, a suitable
recovery was attained when RT was achieved, even after cold
storage.
3.3 Application to evaluation of
nanoformulations
DLS analysis of the nanoformulations revealed particle size
of 225 ± 2 nm for amorphous polymeric dispersion nanopar-
ticles carrying DAP, and 211 ± 3 nm for PLGA poly-
meric nanoparticles carrying CLZ. The obtained nanoparti-
cles exhibited polydispersity index values of 0.187 and 0.129,
respectively. Both values are <0.2, which are consistent with
homogenous populations [32].
Most of the times, assessment of drug entrapment in
nanoparticles is based on non-separative methods, including
direct UV spectrophotometry of drug present in the super-
natant of nanoparticles’ preparation media. This assumes that
drug not present in the supernatant is entrapped, which can
lead to significant errors in quantification. Other issue to
be tackled is the release of drug from nanoparticles matrix
prior to quantification. For this, the nanoformulations were
diluted in water or in ACN/water/acetate buffer (pH 4.8,
50 mM) (40:50:10 v/v/v), following analysis by DLS. In
water, DAP nanoformulations exhibited a population with
an average size around 200 nm. Using ACN/water/acetate
buffer (pH 4.8, 50 mM) (40:50:10 v/v/v) as solvent, no pop-
ulation was detected. Similarly, for CLZ nanoformulations,
the formulation dispersed in water had a population with an
average size of 230 nm. In ACN/water/acetate buffer (pH
4.8, 50 mM) (40:50:10 v/v/v) the population disappeared.
TABLE 2 Stability of DAP and CLZ at different experimental conditions
After 24 h at RT After 3 freeze-thaw cycles
Measured concentration (mg/L) Measured concentration (mg/L)
Compound
Nominal concentration
(mg/L) Mean (mg/L) Accuracy (%) CV (%) Mean (mg/L) Accuracy (%) CV (%)
DAP 0.50 0.56 112 1.8 0.54 108 1.9
2 1.91 95.5 1.6 2.06 103 1
5 5.07 101.4 0.6 4.93 98.6 0.4
CLZ 0.50 0.57 114 1.8 0.49 98 2
2 2.10 105 1.4 1.93 96.5 1
5 4.31 86.2 0.7 4.77 95.4 0.8
Additionally, count rates were 450–480 for nanoparticles in
water and they decreased to background values for nanoparti-
cles in ACN/water/acetate buffer (pH 4.8, 50 mM) (40:50:10
v/v/v). Therefore, a disruption of nanoparticle structure was
observed for both formulations with consequent drug release.
Entrapment efficiency was evaluated as 54.8 ± 0.1% for
DAP and 24.9 ± 0.2% for CLZ. Compared to previously
reported efficiency entrapment values for other formulations,
similar values were obtained for DAP loaded in surface-
functionalized solid lipid nanoparticles based on cetyl palmi-
tate [12], but lower than those reported for theospheres [9].
Concerning CLZ, better entrapment efficiency was reported
for more hydrophobic formulations, based on hypromellose
acetate succinate, lecithin, and zein [13]. This is expected,
considering the hydrophobic character of CLZ.
Concerning permeability studies using Caco-2 cell as a
model of intestinal epithelium [31], the tested formulation
containing both nanoparticles provided values of % perme-
ated amount of 31.3 ± 2.9% for DAP and 10.8 ± 0.8% for
CLZ (after 2 h), and 52.5 ± 9.1% for DAP and 39.4 ± 3.1%
for CLZ (after 8 h), showing the sustained permeation of both
formulations.
4 CONCLUDING REMARKS
An HPLC method coupled with UV detection was devel-
oped and fully validated for quantification of DAP and CLZ
in nanoformulations containing polymers. Separation was
achieved using a core–shell C18 stationary phase and amobile
phase buffered at pH 4.8, with gradient elution that permit-
ted an efficient separation of the target compounds in a single
run. Addition of ACN at 40% v/v allowed the disintegration
of nanoparticle structures for further quantification of active
compounds.
The developed HPLC–UV method proved to be sensitive,
selective, accurate, and precise for the quantitative analysis of
DAP and CLZ, in a concentration range suitable for applica-
tion to nanoformulations. LOD and LOQ values in the μg/L
level were attained, being comparable or even lower than val-
ues previously reported in the literature. The proposed method
was found to be suitable for the determination of drug entrap-
ment efficiency in innovative nanoformulations.
ACKNOWLEDGMENTS
This work received financial support from the European
Union (FEDER funds) and National Funds (FCT/MEC, Fun-
dação para a Ciência e a Tecnologia and Ministério da Edu-
cação e Ciência) under the Partnership Agreement PT2020
UID/QUI/50006/2013-POCI/01/0145/FEDER/007265. E.M.
P. Silva and S. A. C. Lima acknowledge funding from
FEDER-Operational Competitiveness and Internationaliza-
tion Programme (COMPETE 2020) through project NORTE-
01-0145-FEDER-000011. L. Barreiros thanks FCT and
POPH (Programa Operacional Potencial Humano) for her
Post-Doc grant (SFRH/BPD/89668/2012). L. L. Chaves
thanks the CNPq Foundation, Ministry of Education of Brazil
for the Doctoral fellowship 246514/2012-4. Technical assis-
tance from Ms. Manuela Barros is acknowledged.
REFERENCES
1. World Health Organization, Global leprosy update, 2015: time
for action, accountability and inclusion, 2016, 91, 405–420,
http://www.who.int/lep/resources/who_wer9135/en/
2. Smith, C. S., Aerts, A., Saunderson, P., Kawuma, J., Kita, E., Vir-
mond, M., Multidrug therapy for leprosy: a game changer on the
path to elimination. Lancet Infect. Dis. 2017, 17, E293–E297.
3. Yamasaki, P. R., do Nascimento, D. C., Chelucci, R. C., Belone, A.
D. F., Rosa, P. S., Diorio, S. M., de Melo, T. R. F., Barbieri, K. P.,
Placeres, M. C. P., Carlos, I. Z., Chung, M. C., dos Santos, J. L.,
Synthesis and evaluation of novel dapsone-thalidomide hybrids for
the treatment of type 2 leprosy reactions. Bioorg. Med. Chem. Lett.
2014, 24, 3084–3087.
4. Anusuya, S., Natarajan, J., The eradication of leprosy: molecular
modeling techniques for novel drug discovery. Expert. Opin. Drug
Discov. 2013, 8, 1239–1251.
5. Wozel, G., Blasum, C., Dapsone in dermatology and beyond. Arch.
Dermatol. Res. 2014, 306, 103–124.
6. Cholo, M. C., Steel, H. C., Fourie, P. B., Germishuizen, W. A.,
Anderson, R., Clofazimine: current status and future prospects. J.
Antimicrob. Chemother. 2012, 67, 290–298.
7. Chaves, L. L., Lima, S. A. C., Vieira, A. C. C., Barreiros, L.,
Segundo, M. A., Ferreira, D., Sarmento, B., Reis, S., Develop-
ment of PLGA nanoparticles loaded with clofazimine for oral deliv-
ery: assessment of formulation variables and intestinal permeability.
Eur. J. Pharm. Sci. 2018, 112, 28–37.
8. Chaves, L. L., Vieira, A. C. C., Ferreira, D., Sarmento, B., Reis,
S., Rational and precise development of amorphous polymeric sys-
tems with dapsone by response surface methodology. Int. J. Biol.
Macromol. 2015, 81, 662–671.
9. dos Santos, G. S., Pereira, G. G., Bender, E. A., Colome, L. M.,
Guterres, S. S., de Carvalho, D. C. M., Weissmuller, G., Develop-
ment and characterization of lipid nanoparticles for dapsone topical
application. Quim. Nova 2012, 35, 1388-U1530.
10. Rojo, L., Fernandez-Gutierrez,M., Deb, S., Stevens,M.M., Roman,
J. S., Designing dapsone polymer conjugates for controlled drug
delivery. Acta Biomater. 2015, 27, 32–41.
11. Valetti, S., Xia, X., Costa-Gouveia, J., Brodin, P., Bernet-Camard,
M. F., Andersson, M., Feiler, A., Clofazimine encapsulation in
nanoporous silica particles for the oral treatment of antibiotic-
resistant Mycobacterium tuberculosis infections. Nanomedicine
2017, 12, 831–844.
12. Vieira, A. C. C., Chaves, L. L., Pinheiro, M., Ferreira, D., Sarmento,
B., Reis, S., Design and statistical modeling of mannose-decorated
dapsone-containing nanoparticles as a strategy of targeting intesti-
nal M-cells. Int. J. Nanomed. 2016, 11, 2601–2617.
13. Zhang, Y. Y., Feng, J., McManus, S. A., Lu, H. D., Ristroph, K.
D., Cho, E. J., Dobrijevic, E. L., Chan, H. K., Prud'homme, R.
K., Design and solidification of fast-releasing clofazimine nanopar-
ticles for treatment of cryptosporidiosis. Mol. Pharm. 2017, 14,
3480–3488.
14. Salama, N., El Ries, M. A., Toubar, S., Hamide, M. A., Walash, M.
I., Validated TLC and HPLC stability-indicating methods for the
quantitative determination of dapsone. JPC-J. Planar Chromatogr.-
Mod. TLC 2012, 25, 65–71.
15. Kim, H. J., Seo, K. A., Kim, H. M., Jeong, E. S., Ghim, J. L., Lee, S.
H., Lee, Y. M., Kim, D. H., Shin, J. G., Simple and accurate quanti-
tative analysis of 20 anti-tuberculosis drugs in human plasma using
liquid chromatography-electrospray ionization-tandem mass spec-
trometry. J. Pharm. Biomed. Anal. 2015, 102, 9–16.
16. Liu, Y., Li, X., Yang, C. J., Tai, S., Zhang, X. N., Liu, G. F., UPLC-
MS-MS method for simultaneous determination of caffeine, tolbu-
tamide, metoprolol, and dapsone in rat plasma and its application to
cytochrome P450 activity study in rats. J. Chromatogr. Sci. 2013,
51, 26–32.
17. Mberu, E. K., Muhia, D. K., Minyiri, G. O., Njonge, E. W., Watkins,
W. M., Measurement of physiological concentrations of dapsone
and its monoacetyl metabolite: a miniaturised assay for liquid or fil-
ter paper-absorbed samples. J. Chromatogr. B-Biomed. Appl. 1996,
677, 385–387.
18. O'Connor, R., O'Sullivan, J. F., O'Kennedy, R., Determination of
serum and tissue levels of phenazines including clofazimine. J.
Chromatogr. B-Biomed. Appl. 1996, 681, 307–315.
19. Revanasiddappa, H. D., Manju, B., A spectrophotometric method
for the determination of metoclopramide HCl and dapsone. J.
Pharm. Biomed. Anal. 2001, 25, 631–637.
20. Li, H. Z., Ma, S. H., Zhang, H. M., Liu, J. M., Wu, Y. X., Cao,
P. Q., Gao, X., Nano carrier mediated co-delivery of dapsone and
clofazimine for improved therapeutic efficacy against tuberculosis
in rats. Biomed. Res.-India 2017, 28, 1284–1289.
21. Kwadijk, S., Torano, J. S., High-performance liquid chromato-
graphic method with ultraviolet detection for the determination of
dapsone and its hydroxylated metabolite in human plasma. Biomed.
Chromatogr. 2002, 16, 203–208.
22. Segundo, M. A., Abreu, V., Osorio, M. V., Nogueira, S., Lin, P. K.
T., Cordeiro-da-Silva, A., Lima, S. A. C., Development and valida-
tion of HPLC method with fluorometric detection for quantification
of bisnaphthalimidopropyldiaminooctane in animal tissues follow-
ing administration in polymeric nanoparticles. J. Pharm. Biomed.
Anal. 2016, 120, 290–296.
23. Cunha, R. R., Ribeiro, M., Munoz, R. A. A., Richter, E. M.,
Fast determination of codeine, orphenadrine, promethazine, scopo-
lamine, tramadol, and paracetamol in pharmaceutical formulations
by capillary electrophoresis. J. Sep. Sci. 2017, 40, 1815–1823.
24. Paul, P., Duchateau, T., Sanger-van de Griend, C., Adams, E., Van
Schepdael, A., Capillary electrophoresis with capacitively coupled
contactless conductivity detection method development and valida-
tion for the determination of azithromycin, clarithromycin, and clin-
damycin. J. Sep. Sci. 2017, 40, 3535–3544.
25. Zhang, Q., Yang, F. Q., Ge, L. Y., Hu, Y. J., Xia, Z. N., Recent appli-
cations of hydrophilic interaction liquid chromatography in pharma-
ceutical analysis. J. Sep. Sci. 2017, 40, 49–80.
26. Yamamoto, E., Hyodo, K., Ohnishi, N., Suzuki, T., Ishihara, H.,
Kikuchi, H., Asakawa, N., Direct, simultaneous measurement of
liposome-encapsulated and released drugs in plasma by on-line
SPE-SPE-HPLC. J. Chromatogr. B 2011, 879, 3620–3625.
27. Kimoto, A., Watanabe, A., Yamamoto, E., Higashi, T., Kate, M.,
Rapid analysis of DOXIL stability and drug release from DOXIL
by HPLC using a glycidyl methacrylate-coated monolithic column.
Chem. Pharm. Bull. 2017, 65, 945–949.
28. Xie, Y. P., Shao, N., Jin, Y., Zhang, L., Jiang, H., Xiong, N. J.,
Su, F. M., Xu, H. Y., Determination of non-liposomal and liposo-
mal doxorubicin in plasma by LC-MS/MS coupled with an effective
solid phase extraction: In comparison with ultrafiltration technique
and application to a pharmacokinetic study. J. Chromatogr. B 2018,
1072, 149–160.
29. European Medicines Agency, Guideline on bioanalytical method
validation EMEA/CHMP/EWP/192217/2009, 2011.
30. ICH guideline Q2(R1): Validation of Analytical Procedures: Text
and Methodology 541 (2005).
31. Chaves, L. L., Lima, S. A. C., Vieira, A. C. C., Barreiros, L.,
Segundo, M. A., Ferreira, D., Sarmento, B., Reis, S., Nanosys-
tems as modulators of intestinal dapsone and clofazimine delivery.
Biomed. Pharmacother. 2018, 103, 1392–1396.
32. Mitri, K., Shegokar, R., Gohla, S., Anselmi, C., Muller, R. H., Lipid
nanocarriers for dermal delivery of lutein: Preparation, characteri-
zation, stability and performance. Int. J. Pharm. 2011, 414, 267–
275.
